Portage Biotech Stock Shares Owned By Institutions
PRTG Stock | USD 4.41 0.15 3.29% |
Portage Biotech fundamentals help investors to digest information that contributes to Portage Biotech's financial success or failures. It also enables traders to predict the movement of Portage Stock. The fundamental analysis module provides a way to measure Portage Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Portage Biotech stock.
Portage | Shares Owned By Institutions |
Portage Biotech Company Shares Owned By Institutions Analysis
Portage Biotech's Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
More About Shares Owned By Institutions | All Equity Analysis
Shares Held by Institutions | = | Funds and Banks | + | Firms |
Current Portage Biotech Shares Owned By Institutions | 17.80 % |
Most of Portage Biotech's fundamental indicators, such as Shares Owned By Institutions, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Portage Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Portage Shares Owned By Institutions Driver Correlations
Understanding the fundamental principles of building solid financial models for Portage Biotech is extremely important. It helps to project a fair market value of Portage Stock properly, considering its historical fundamentals such as Shares Owned By Institutions. Since Portage Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Portage Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Portage Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Since Institution investors conduct a lot of independent research they tend to be more involved and usually more knowledgeable about entities they invest as compared to amateur investors.
Competition |
Based on the latest financial disclosure, 17.804% of Portage Biotech are shares owned by institutions. This is 60.12% lower than that of the Biotechnology sector and 62.52% lower than that of the Health Care industry. The shares owned by institutions for all United States stocks is 54.59% higher than that of the company.
Portage Shares Owned By Institutions Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Portage Biotech's direct or indirect competition against its Shares Owned By Institutions to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Portage Biotech could also be used in its relative valuation, which is a method of valuing Portage Biotech by comparing valuation metrics of similar companies.Portage Biotech is currently under evaluation in shares owned by institutions category among its peers.
Portage Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Portage Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Portage Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Portage Fundamentals
Return On Equity | -1.91 | ||||
Return On Asset | -0.19 | ||||
Current Valuation | 5.52 M | ||||
Shares Outstanding | 1.65 M | ||||
Shares Owned By Insiders | 29.80 % | ||||
Shares Owned By Institutions | 17.80 % | ||||
Number Of Shares Shorted | 19.77 K | ||||
Price To Book | 5.19 X | ||||
EBITDA | (18.2 M) | ||||
Net Income | (75.34 M) | ||||
Cash And Equivalents | 21.18 M | ||||
Cash Per Share | 1.25 X | ||||
Total Debt | 47 K | ||||
Current Ratio | 11.73 X | ||||
Book Value Per Share | 4.07 X | ||||
Cash Flow From Operations | (14.3 M) | ||||
Short Ratio | 0.17 X | ||||
Earnings Per Share | (68.17) X | ||||
Target Price | 140.0 | ||||
Beta | 99.48 | ||||
Market Capitalization | 7.26 M | ||||
Total Asset | 7.78 M | ||||
Retained Earnings | (239.32 M) | ||||
Working Capital | 4.82 M | ||||
Net Asset | 7.78 M |
About Portage Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Portage Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Portage Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Portage Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
EBR | Centrais Electricas Brasileiras | |
HE | Hawaiian Electric Industries | |
VFC | VF Corporation | |
BVHMF | Vistry Group PLC | |
S | SentinelOne |
Check out Portage Biotech Piotroski F Score and Portage Biotech Altman Z Score analysis. For more detail on how to invest in Portage Stock please use our How to Invest in Portage Biotech guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Portage Biotech. If investors know Portage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Portage Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Portage Biotech is measured differently than its book value, which is the value of Portage that is recorded on the company's balance sheet. Investors also form their own opinion of Portage Biotech's value that differs from its market value or its book value, called intrinsic value, which is Portage Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Portage Biotech's market value can be influenced by many factors that don't directly affect Portage Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Portage Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Portage Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Portage Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.